Head, Department of Peripheral and Vascular, The Madras Medical Mission Hospital, Chennai, Tamil Nadu, India, Corresponding Author.
Interventional Cardiologist, Department of Cardiology, Medicover Hospital, Sangamner, Mumbai, Maharashtra, India.
J Assoc Physicians India. 2024 Sep;72(9S):19-23. doi: 10.59556/japi.72.0672.
Heart failure (HF) is the fastest-growing disease with a higher fatality rate. The most differentiating feature of HF is pulmonary or peripheral edema, which is characterized by a gradient between intravascular and extravascular pressure. Loop diuretics were chosen as the primary treatment for edema associated with HF due to their efficacy and early onset of action. If an oral dose had not been provided, intravenous (IV) administration of torsemide, or equal doses of furosemide and bumetanide, was preferred. However, the key variables for selecting and administering loop diuretics are their pharmacological qualities as well as their clinical efficacy. Torsemide has greater bioavailability, a higher rate of absorption, a longer duration of action, and lesser ototoxicity, making it the primary choice in the management of edematous HF.
心力衰竭（HF）是发病率增长最快的疾病。HF 的最显著特征是肺或外周水肿，其特征是血管内和血管外压力之间存在梯度。由于袢利尿剂的疗效和起效迅速，因此被选为 HF 相关水肿的主要治疗药物。如果未提供口服剂量，则首选静脉（IV）给予托塞米，或给予相等剂量的呋塞米和布美他尼。然而，选择和给予袢利尿剂的关键变量是其药理学特性及其临床疗效。托塞米具有更高的生物利用度、更快的吸收率、更长的作用持续时间和较少的耳毒性，使其成为治疗水肿性 HF 的首选药物。
